Drug Profile
Research programme: transdermal Parkinson's disease therapeutics - Corium International
Alternative Names: Corplex ropinirole - Corium International; Pramipexole TDS - Corium International; Pramipexole transdermal - Corium International; Ropinirole TDS - Corium International; Ropinirole transdermal - Corium InternationalLatest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator Corium International
- Class Amines; Antiparkinsonians; Benzothiazoles; Indoles; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 22 Aug 2023 Discontinued - Preclinical for Parkinson's disease in USA (Transdermal) (Corium pipeline, August 2023)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Transdermal)
- 17 Dec 2018 Corium International has been acquired by Gurnet point capital